RaySightMed Completes Hundred-Million-RMB Financing with Support from Two Tianjin State-Owned Investors, Accelerating Industrial Deployment of Full Product Portfolio

Recently, RaySightMed officially announced the completion of a new strategic financing round of nearly RMB 100 million. This round was jointly invested by Haihe River Industry Fund and state-owned industrial capital at both the municipal and district levels through Zhongli Fund. With the project officially establishing its presence in Tianjin, the company will accelerate the industrial expansion of its full product portfolio and the large-scale promotion of its offerings in the northern China market.

The closing of this round of funding represents strong recognition from the capital market of RaySightMed's mature product clinical value, commercial capabilities, and long-term industrial strategy. Leveraging this financing opportunity, RaySightMed will establish a solid industrial presence in Tianjin, setting up standardized production facilities and building a high-end medical device mass production system. Through the dual approach of a production base and a regional marketing center, the company will comprehensively serve the core medical markets of northern, northeastern, and northwestern China, filling gaps in its national industrialization and channel coverage, and providing a solid foundation of production capacity and service support for the rapid market expansion of its currently approved products.

This round of financing will focus on advancing the commercial promotion and production capacity upgrades for the company's full product portfolio, with priority given to the coronary functional assessment, non-invasive coronary evaluation, and intracardiac echocardiography product lines, aiming to continuously expand the clinical penetration and market share of domestically developed innovative cardiovascular devices.

In the field of intraoperative precision interventional diagnosis and treatment, the AngioQFA coronary functional fractional flow reserve and index of microcirculatory resistance measurement system is the company's core benchmark product and a key tool for standardized functional assessment in coronary intervention in China. The product enables one-stop precise measurement of core functional parameters including fractional flow reserve and index of microcirculatory resistance, simultaneously completing dual precise assessments of coronary blood supply function and microcirculatory function. It accurately guides physicians in developing personalized interventional strategies, effectively addressing the clinical limitation of traditional angiography which "assesses morphology but not function," and significantly improving the precision, safety, and standardization of interventional procedures. At present, this product has achieved routine clinical application and has become a standardized essential device for interventional departments.

In the field of non-invasive pre-screening, RaySightMed, as a leading domestic non-invasive coronary functional assessment product, leverages proprietary hemodynamic simulation and artificial intelligence algorithms to accurately complete coronary ischemic functional assessment and lesion risk stratification without the need for invasive intervention. It effectively optimizes the entire clinical pathway of coronary artery disease screening, referral, and pre-operative evaluation, significantly reducing procedural trauma and healthcare costs for patients. Widely applicable for large-scale early screening and precise pre-operative assessment, it is a benchmark product in the field of non-invasive precision cardiovascular diagnosis and treatment.

In the field of intracardiac precision imaging, the RaySightMed Intracardiac Echocardiography system completes the company's full-chain diagnosis and treatment closed loop for cardiovascular diseases. Leveraging its core advantages of high-definition real-time imaging, strong minimally invasive adaptability, and broad procedural compatibility, the product deeply serves complex minimally invasive interventional procedures such as structural heart disease and cardiac arrhythmias, providing comprehensive imaging support for intraoperative precise positioning, device navigation, and outcome assessment. To date, the company has established a mature product matrix integrating intraoperative functional assessment, non-invasive pre-screening, and intracardiac precision imaging, comprehensively covering the mainstream clinical diagnosis and treatment scenarios in cardiovascular care.

Leveraging the high-end manufacturing capacity of the newly established production base in Tianjin, the company will significantly improve the delivery efficiency, supply capability, and quality control standards for its three flagship products. Through the localized operations system of its northern sales center, the company will comprehensively strengthen its capabilities in academic promotion, clinical training, channel development, and after-sales support in the northern region, accelerating the scaled market expansion of its mature products and continuously consolidating RaySightMed's leading position in the domestic cardiovascular intelligent diagnosis and treatment device sector.

Building on the commercialization of its mature products, RaySightMed continues to extend the boundaries of its diagnosis and treatment services, establishing an integrated intelligent diagnosis and treatment closed-loop solution covering the full lifecycle of cardiovascular diseases, including early screening and warning, intraoperative precision treatment, post-operative follow-up and intervention, and long-term chronic disease management.

Currently, the cardiovascular disease landscape in China faces challenges including a large patient population, high post-operative recurrence rates, non-standardized post-discharge follow-up, and a lack of refined disease management. Leveraging its years of accumulated core artificial intelligence hemodynamic algorithms, vast real-world clinical data, and standardized hardware and software product systems, RaySightMed has successfully established a complete service chain spanning pre-hospital non-invasive precision screening, in-hospital personalized precision treatment, and post-hospital digital follow-up management.

Looking ahead, the company will leverage Tianjin's abundant regional medical resources and its strategic position in the northern market to deeply implement refined chronic disease management programs for cardiovascular conditions. Through intelligent digital tools, the company will assist partner hospitals in establishing standardized and routine chronic disease follow-up and health management systems, enabling early detection, early intervention, and early management of cardiovascular diseases, effectively reducing post-operative recurrence rates, and driving the transformation of China's cardiovascular diagnosis and treatment model from "single-procedure intervention" to "full-cycle health management."

While consolidating its existing product commercialization and chronic disease management foundation, RaySightMed is directing the medium- and long-term strategic resources from this financing round toward the frontier field of artificial intelligence-powered vascular interventional surgical robots, focusing on overcoming core technological challenges in next-generation minimally invasive interventions to build long-term core technology barriers and future growth trajectories.

Addressing the industry shortcomings of traditional interventional surgical robots—which are heavily focused on mechanical control, low in intelligence, and poorly adapted to complex lesions—RaySightMed's artificial intelligence-powered vascular interventional surgical robot offers differentiated advantages through native artificial intelligence empowerment, a full-process intelligent closed loop, and adaptive precision operation. The product deeply integrates four core underlying technologies: the company's proprietary hemodynamic simulation foundation model, real-time intracavitary imaging artificial intelligence recognition, autonomous intelligent artificial intelligence surgical pathway planning, and artificial intelligence automated precision control of minimally invasive instruments, achieving deep integration of algorithms and hardware.

Leveraging its proprietary leading artificial intelligence computing platform, the robot can analyze vascular structure, hemodynamic function, plaque characteristics, and microcirculatory status within milliseconds during surgery, automatically identify high-risk procedural points, intelligently generate optimal surgical strategies and delivery pathways, and perform refined minimally invasive operations through artificial intelligence self-adaptation. This completely breaks through the limitations of traditional robots characterized by "machine-assisted, human-dominated" operation, realizing a new surgical paradigm of artificial intelligence active assistance, intelligent decision-making, and precision treatment.

The product can efficiently adapt to various high-difficulty interventional procedures including complex coronary lesions and microcirculatory lesions, significantly reducing the threshold for advanced interventional procedures, shortening the physician learning curve, and improving the standardization of interventional care nationwide. Its overall technical architecture and intelligent capabilities rank among the domestic leading and international first-tier levels.

Looking ahead, RaySightMed will fully leverage Tianjin's comprehensive high-end manufacturing industrial infrastructure, high-quality supply chain ecosystem, and abundant top-tier clinical resources to continuously accelerate product iteration, performance optimization, type testing, and multi-center prospective clinical studies for its artificial intelligence interventional surgical robot. The company will steadily advance the clinical translation and industrial deployment of cutting-edge technologies, positioning itself in the future golden track of intelligent minimally invasive interventions, and continue to lead the innovative field of artificial intelligence-powered precision cardiovascular diagnosis and treatment.